Abstract
Objection
To evaluate the impact of fertility-preserving surgery and adjuvant chemotherapy on survival and fertility of young patients with ovarian malignant tumors.
Methods
Retrospective analysis of 39 patients with ovarian malignant germ cell tumors, 23 patients with malignant epithelial tumors and 4 patients with sexual cord mesenchymal tumors receiving conservative treatments.
Results
Two patients lost follow-up (we do not statistics them). Fifty-nine among 64 patients were alive up to now (92.19%). The overall survival rate for ovarian epithelial malignancies, malignant germ cell tumors and sexual cord mesenchymal tumors were 95.45%, 89.47% and 100% respectively. Fifteen patients received second operation and recurrence was found in 6 patients. Among the 59 surviving patients, 53 patients have normal menstruation. Thirteen patients among 20 patients who want to pregnant have 15 pregnancies and 9 successful deliveries.
Conclusion
The management of fertility-preserving surgery on patients with ovarian malignant germ cell tumors, whatever the FIGO staging is, is a safe option. For patients with ovarian epithelial carcinomas, fertility-preserving surgery only confined to low-stage (stage I), low-grade (G1), and patients who want keep fertility function seriously. Cisplatinum-based combination chemotherapy is necessary. Standardized chemotherapy has no affection on fertility function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Peccatori F, Bonazzi C, Chiari S, et al. Surgical management of malignant ovarian germ cell tumors: 10 year’s experience of 129 patients. Obstet Gynecol, 1995, 86: 367–372.
El-Lamie, IK, Shehata NA, Abou-Loz SK, et al. Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol, 2000, 21: 605–609.
Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol, 2003, 24: 223–232.
Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Gynecol Oncol, 1997, 64: 160–165.
Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol, 1994, 12: 701–706.
Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol, 1992, 166: 788–793.
Meistrich M, Vasslopoulou-Sellin R, Lipshultz L. Gonadal dysfunction In: Rosemberg S, ed. Cancer, principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997. 2758–2773.
Tangir J, Zelterman D, Ma W, et al. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol, 2003, 101: 251–257.
Meistrich M, Vasslopoulou-Sellin R, Lipshultz L. Gonadal dysfunction In: Rosemberg S, ed. Cancer, principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997. 2758–2773.
Green DM, Zevon MA, Lowrie G, et al. Congenital anomalies in children of patients who received chemotherapy for cancer in children and adolescence. N Engl J Med, 1991, 325: 141–146.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hou, M., Xi, M., Cao, Z. et al. Evaluation the effect of fertility-preserving surgery on young patients with malignant ovarian tumors. Chinese German J Clin Oncol 5, 446–450 (2006). https://doi.org/10.1007/s10330-006-0516-8
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10330-006-0516-8